α-Solanine as potential therapeutic target in pulmonary artery hypertension

Affiliations

¹ aDepartment of Cardiology, Yanbian University Hospital, Yanji, Jilin, China bDepartment of Cardiology, Gifu Prefectural, Tajimikenlitsu Hospital, Tajimi, Gifu Prefecture, Japan cDepartment of Cardiology, The Forth Hospital of Harbin Medical University, Harbin, Heilongjiang, China dDepartment of Internal Medicine, Kyung Hee University, Seoul, South Korea eInstitute of Innovation for the Future Society, Nagoya University Graduate School of Medicine, Nagoya, Aichi Prefecture, Japan.

Comment

Xianwu Cheng et al. J Hypertens. 2017 Dec.

. 2017 Dec;35(12):2377-2379.

doi: 10.1097/HJH.0000000000001483.

¹ aDepartment of Cardiology, Yanbian University Hospital, Yanji, Jilin, China bDepartment of Cardiology, Gifu Prefectural, Tajimikenlitsu Hospital, Tajimi, Gifu Prefecture, Japan cDepartment of Cardiology, The Forth Hospital of Harbin Medical University, Harbin, Heilongjiang, China dDepartment of Internal Medicine, Kyung Hee University, Seoul, South Korea eInstitute of Innovation for the Future Society, Nagoya University Graduate School of Medicine, Nagoya, Aichi Prefecture, Japan.

No abstract available

Comment on

α-Solanine reverses pulmonary vascular remodeling and vascular angiogenesis in experimental pulmonary artery hypertension.
Nie X, Dai Y, Tan J, Chen Y, Qin G, Mao W, Zou J, Chang Y, Wang Q, Chen J. Nie X, et al. J Hypertens. 2017 Dec;35(12):2419-2435. doi: 10.1097/HJH.0000000000001475. J Hypertens. 2017. PMID: 28704260